Psoriatic Arthritis News and Research

RSS
Like rheumatoid arthritis (RA), psoriatic arthritis is a chronic inflammatory disease of the joints and connective tissue. The disease causes joint pain and swelling that can lead to crippling along with inflamed and irritated scaly red patches of skin throughout the body. It is a progressive and debilitating disease and because there are no treatments specifically approved for psoriatic arthritis, doctors often use therapies approved for RA, including nonsteroidal anti-inflammatory drugs (NSAIDs) and disease modifying anti-rheumatic drugs (DMARDs). However, no DMARDs are currently approved for use in psoriatic arthritis. There are approximately 300,000 patients with psoriatic arthritis in the United States and the disease affects both men and women most commonly between the ages 30 and 50. Psoriatic arthritis patients are generally treated by rheumatologists and dermatologists.
Diagnostic value of ultrasound in comparing different types of arthritis

Diagnostic value of ultrasound in comparing different types of arthritis

Study shows link between BMI and disease severity in psoriatic arthritis

Study shows link between BMI and disease severity in psoriatic arthritis

Finding potential treatments for autoimmune diseases

Finding potential treatments for autoimmune diseases

ACR and Arthritis Foundation release two guidelines on juvenile idiopathic arthritis

ACR and Arthritis Foundation release two guidelines on juvenile idiopathic arthritis

ACR and NPF release joint treatment guideline for psoriatic arthritis

ACR and NPF release joint treatment guideline for psoriatic arthritis

NPF grants support advancement of psoriatic disease research

NPF grants support advancement of psoriatic disease research

AbbVie’s U-ACHIEVE Phase 2b/3 dose-ranging study improves outcomes in patients with ulcerative colitis

AbbVie’s U-ACHIEVE Phase 2b/3 dose-ranging study improves outcomes in patients with ulcerative colitis

Gilead Sciences presents Phase 3 results of filgotinib in biologic-experienced rheumatoid arthritis at 2018 ACR/ARHP Annual Meeting

Gilead Sciences presents Phase 3 results of filgotinib in biologic-experienced rheumatoid arthritis at 2018 ACR/ARHP Annual Meeting

Survey: Psoriasis patients expect treatment to go beyond just clear skin and safety

Survey: Psoriasis patients expect treatment to go beyond just clear skin and safety

Price check on drug ads: Would revealing costs help patients control spending?

Price check on drug ads: Would revealing costs help patients control spending?

FDA approves first oral medication for adults with moderately to severely active ulcerative colitis

FDA approves first oral medication for adults with moderately to severely active ulcerative colitis

Study: Psoriasis patients taking Humira show no change in aortic inflammation

Study: Psoriasis patients taking Humira show no change in aortic inflammation

New study launched to examine effects of rheumatologic agent on bone health

New study launched to examine effects of rheumatologic agent on bone health

BWH bioengineers develop flare-responsive hydrogel to treat arthritis

BWH bioengineers develop flare-responsive hydrogel to treat arthritis

New low-cost microfluidic device brings single-cell technology to bedside

New low-cost microfluidic device brings single-cell technology to bedside

Psoriasis drug also effective at reducing aortic inflammation

Psoriasis drug also effective at reducing aortic inflammation

Researchers discover link between rheumatoid arthritis and bacteria in milk

Researchers discover link between rheumatoid arthritis and bacteria in milk

Researchers win $6.5 million NIH grant to personalize diagnosis and treatment of psoriasis

Researchers win $6.5 million NIH grant to personalize diagnosis and treatment of psoriasis

New guidelines for anti-rheumatic drug management in patients having joint replacement surgery

New guidelines for anti-rheumatic drug management in patients having joint replacement surgery

Research findings provide insight into mechanisms underlying differences in efficacy of anti-TNF drugs

Research findings provide insight into mechanisms underlying differences in efficacy of anti-TNF drugs